QT
ADAP

Quantamental Technologies’s Adaptimmune Therapeutics ADAP Stock Holding History

Quantamental Technologies’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-700
Closed -$1K – 426
2019
Q3 		$1K Hold
700
– – ﹤0.01% 1462
2019
Q2 		$3K Hold
700
– – ﹤0.01% 1352
2019
Q1 		$3K Buy
700
+100
+17% +$466 ﹤0.01% 1353
2018
Q4 		$3K Buy
+600
New +$4.43K ﹤0.01% 1254

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Quantamental Technologies's ADAP Position: Q4 2019 in Review

Quantamental Technologies sold out of Adaptimmune Therapeutics (ADAP) in Q4 2019, closing a stake of 700 shares — an estimated $1K sold.

Quantamental Technologies first reported a position in ADAP in Q4 2018 and held it in 4 quarters. The position peaked at $3K in Q2 2019. 43 funds tracked by Wall St. Rank hold ADAP as of Q4 2019.

  • Quantamental Technologies reported no remaining Adaptimmune Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Quantamental Technologies sold 700 Adaptimmune Therapeutics shares in Q4 2019, an estimated $1K.
  • Quantamental Technologies first reported a position in Adaptimmune Therapeutics in Q4 2018 and held it in 4 quarters.
  • Quantamental Technologies's Adaptimmune Therapeutics position peaked at $3K in Q2 2019.
  • 43 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2019.

Based on Quantamental Technologies's 13F filing for Q4 2019, filed 14 Feb 2020.